Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $29.06
America/New_York / 23 feb 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 271.79 mill |
EPS: | -2.01 |
P/E: | -14.46 |
Earnings Date: | Nov 03, 2022 |
SharesOutstanding: | 43.76 mill |
Avg Daily Volume: | 0.626 mill |
RATING 2023-03-03 |
---|
B+ |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | n/a | n/a | ||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -14.46 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.46x |
Company: PE -14.46 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 28.20 - 29.92 ( +/- 2.96%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-24 | 5am Partners Vi, Llc | Sell | 496 323 | Common Stock |
2023-02-24 | Healy James | Sell | 9 803 | Common Stock |
2022-11-28 | Healy James | Sell | 6 000 | Common Stock |
2023-02-24 | Healy James | Sell | 19 608 | Common Stock |
2023-02-24 | Healy James | Sell | 6 073 949 | Common Stock |
INSIDER POWER |
---|
-68.62 |
Last 98 transactions |
Buy: 39 839 974 | Sell: 98 795 779 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $29.06 (0.00% ) |
Volume | 0 mill |
Avg. Vol. | 0.626 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.